Mauna Kea Technologies Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Mauna Kea Technologies kazanç ve gelirinin sırasıyla yıllık 14.3% ve 8% oranında artması tahmin edilirken, EPS'nin yıllık 12.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

14.3%

Kazanç büyüme oranı

12.7%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	14.2%
Gelir büyüme oranı	8.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	05 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:1MK - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	9	-8	-7	-6	1
12/31/2025	8	-8	-8	-7	1
12/31/2024	7	-9	-15	-8	1
6/30/2024	8	-11	-8	-7	N/A
3/31/2024	10	-7	-4	-4	N/A
12/31/2023	11	-4	-1	-1	N/A
9/30/2023	11	-3	-1	0	N/A
6/30/2023	12	-2	0	0	N/A
3/31/2023	10	-7	-4	-4	N/A
12/31/2022	8	-11	-9	-9	N/A
9/30/2022	8	-12	-10	-10	N/A
6/30/2022	8	-13	-11	-11	N/A
3/31/2022	8	-13	-11	-11	N/A
12/31/2021	9	-13	-11	-10	N/A
9/30/2021	8	-13	-11	-10	N/A
6/30/2021	8	-13	-11	-10	N/A
3/31/2021	8	-13	-10	-9	N/A
12/31/2020	7	-13	-9	-8	N/A
9/30/2020	7	-13	-10	-9	N/A
6/30/2020	7	-14	-12	-10	N/A
3/31/2020	8	-15	-12	-10	N/A
12/31/2019	9	-15	-12	-10	N/A
9/30/2019	9	-15	-11	-10	N/A
6/30/2019	9	-14	-11	-9	N/A
3/31/2019	9	-13	-12	-10	N/A
12/31/2018	8	-13	-12	-11	N/A
9/30/2018	8	-12	-11	-11	N/A
6/30/2018	7	-11	-11	-10	N/A
3/31/2018	8	-11	N/A	-10	N/A
12/31/2017	8	-10	N/A	-10	N/A
9/30/2017	8	-10	N/A	-9	N/A
6/30/2017	8	-11	N/A	-9	N/A
3/31/2017	9	-10	N/A	-8	N/A
12/31/2016	10	-10	N/A	-8	N/A
9/30/2016	10	-10	N/A	-8	N/A
6/30/2016	10	-10	N/A	-8	N/A
3/31/2016	10	-11	N/A	-10	N/A
12/31/2015	10	-13	N/A	-12	N/A
9/30/2015	11	-13	N/A	-12	N/A
6/30/2015	12	-14	N/A	-13	N/A
3/31/2015	12	-14	N/A	-13	N/A
12/31/2014	12	-14	N/A	-13	N/A
9/30/2014	12	-13	N/A	-12	N/A
6/30/2014	11	-12	N/A	-11	N/A
3/31/2014	11	-12	N/A	-10	N/A
12/31/2013	11	-12	N/A	-10	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1MK önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 1MK önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 1MK önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 1MK şirketinin gelirinin (yıllık 8% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1MK şirketinin gelirinin (yıllık 8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1MK 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Mauna Kea Technologies Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Mauna Kea Technologies Sa Reaffirms Sales Guidance for the Year 2024

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

First half 2024 earnings released

Mauna Kea Technologies Sa Reaffirms Sales Guidance for the Year 2024

Mauna Kea Technologies Announces Positive Clinical Results in Lung Cancer Obtains with Cellvizio

Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 30, 2024

Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 02, 2024

New major risk - Negative shareholders equity

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

New minor risk - Financial data availability

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Mauna Kea Technologies SA ADR - Sponsored to Be Deleted from OTC Equity

New major risk - Share price stability

Mauna Kea Technologies SA announced that it expects to receive €6 million in funding from Telix Pharmaceuticals Limited

Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer

No longer forecast to breakeven

New major risk - Revenue and earnings growth

New minor risk - Share price stability

First half 2023 earnings released: EPS: €0.063 (vs €0.14 loss in 1H 2022)

New major risk - Revenue and earnings growth

Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone

No longer forecast to breakeven

Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer

Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio®

Mauna Kea Technologies SA to Report First Half, 2023 Results on Sep 28, 2023

Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer

No longer forecast to breakeven

Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology

Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive Officer

Mauna Kea Technologies SA to Report First Half, 2022 Final Results on Oct 20, 2022

Mauna Kea Technologies SA to Report First Half, 2022 Results on Oct 20, 2022

No longer forecast to breakeven

No longer forecast to breakeven

Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures

Mauna Kea Technologies SA Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial

Mauna Kea Technologies SA announced that it has received $12.8 million in funding from Lightspeed China Partners, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Shanghai Ivy Investment Holdings Co., Ltd.

First half 2021 earnings released

Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent

Mauna Kea Technologies SA Provides Earnings Guidance for the Twelve Months Ending December 31, 2021

Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Full year 2020 earnings released

Mauna Kea Technologies: Cellvizio® Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification

New 90-day high: €1.55

Mauna Kea Technologies SA to Report Q2, 2021 Results on Jul 22, 2021

Mauna Kea Technologies Announces Board Changes

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announces Exclusive Scientific and Clinical Research Collaboration

New 90-day low: €1.00

New 90-day high: €1.51

New 90-day low: €1.04

New 90-day low - €1.14

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin